Compare Mesoblast Limited (MESO) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Sprott Uranium Miners ETF — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Sprott Uranium Miners ETF trades at $49.69. The key difference: Mesoblast Limited is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| MESO | URNM | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $20.96 | $83.99 |
52-Week Low | $12.88 | $44.14 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
URNM trades at $48.25, up 0.06% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF focuses on uranium miners, benefiting from rising nuclear energy demand driven by AI power needs. Recent news highlights strong performance, with URNM up 26% year-to-date as of April 2026, though some articles question miner valuations versus uranium prices.
The outlook for URNM is supported by long-term nuclear energy growth, but risks include volatility in uranium prices and concentrated miner exposure. Analyst sentiment is mixed, with some seeing upside from AI-driven power demand, while others caution on supply chain gaps and equity optimism diverging from fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
